Alemao E, et al. - Researchers examined how antibody titers are associated with mortality in rheumatoid arthritis and how disease-modifying antirheumatic drugs (DMARDs) modify this association. Using administrative claims data linked to laboratory results, they identified 53,849 and 79,926 patients with evaluable anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF) status, respectively. Patients with RA showed increased mortality in independent correlation with elevated ACPA/RF titers. Patients treated with cDMARDs but not with bDMARDs showed the persistence of these elevated titers.